15 completed, 1 active not recruiting, 1 terminated. 8 Phase 3, 7 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
| Phase 2 | 7 | Completed 6, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Palivizumab: new trials by email Literature Review of Palivizumab trials Research Report on Palivizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease Palivizumab 15 mg/kg - Respiratory Syncytial Virus (RSV) | Not applicable | Active not recruiting | AstraZeneca | 21 | 2025-12-10 | 2026-09-09 |
| Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) Clesrovimab, Palivizumab, Placebo - RSV Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1003 | 2021-11-30 | 2026-05-08 |
| Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV Palivizumab, Placebo, RSV-A Memphis 37b virus - Healthy Adult Participants | Phase 1 | Completed | mAbxience Research S.L. | 56 | 2020-07-06 | 2021-10-04 |
| A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children MEDI8897, Palivizumab - Respiratory Syncytial Virus Infections | Phase 2 / Phase 3 | Completed | AstraZeneca | 925 | 2019-07-30 | 2023-09-21 |
| A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus Palivizumab - Respiratory Syncytial Virus (RSV) | Phase 3 | Completed | AbbVie | 50 | 2016-11-09 | 2018-03-13 |
| "Palivizumab Therapy for RSV-bronchiolitis" Palivizumab, Placebo - Respiratory Syncytial Virus-bronchiolitis | Phase 3 | Completed | Hamad Medical Corporation | 420 | 2014-09-01 | 2018-02-27 |
| Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. Ad-RTS-hIL-12 and Veledimex, Palifosfamide - Breast Cancer Nos Metastatic Recurrent | Phase 2 | Terminated | Alaunos Therapeutics | 12 | 2013-04-04 | 2025-08-28 |
| Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Palivizumab - Respiratory Syncytial Virus Infection | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 28 | 2011-08-01 | 2013-06-17 |
| Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children palivizumab - Respiratory Syncytial Virus Infection, Premature Birth | Phase 2 / Phase 3 | Completed | Abbott | 100 | 2009-11-01 | 2011-07-19 |
| Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice. - Respiratory Syncytial Virus Infection | Completed | Abbott | 82 | 2007-09-01 | 2012-10-31 | |
| Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season Motavizumab, palivizumab, Palivizumab, motavizumab, Motavizumab - Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or | Phase 2 | Completed | MedImmune LLC | 260 | 2006-04-01 | 2012-12-11 |
| A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease Motavizumab, Palivizumab - Congenital Heart Disease | Phase 2 | Completed | MedImmune LLC | 1236 | 2005-10-01 | 2012-02-16 |
| Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) Lyophilized Palivizumab, Liquid Palivizumab - Chronic Lung Disease | Phase 4 | Completed | MedImmune LLC | 417 | 2005-10-01 | 2018-06-27 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children motavizumab (MEDI-524), palivizumab 15 mg/kg - Motavizumab Administration for a Second Season for RSV Prophylaxis | Phase 1 / Phase 2 | Completed | MedImmune LLC | 136 | 2005-05-01 | 2013-05-22 |
| Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children motavizumab (MEDI-524), palivizumab - Respiratory Syncytial Virus Infections | Phase 3 | Completed | MedImmune LLC | 6635 | 2004-11-01 | 2013-08-28 |
| A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis) MEDI-493 - -Unhealthy Children With a History of Prematurity | Phase 2 | Completed | MedImmune LLC | 150 | 2002-09-01 | 2010-11-15 |
| Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation palivizumab, ribavirin - Cancer | Phase 3 | Completed | Fred Hutchinson Cancer Center | 1999-02-01 | 2010-04-02 |
Respiratory Syncytial Virus Infections (7) · Breast Neoplasms (2) · Bronchopulmonary Dysplasia (2) · Heart Defects, Congenital (2) · Infections (2) · Premature Birth (2) · Blast Crisis (1) · Bronchiolitis (1) · Burkitt Lymphoma (1) · Carcinoma, Embryonal (1) · Carcinoma, Ovarian Epithelial (1) · Congenital chloride diarrhea (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Endodermal Sinus Tumor (1) · Hodgkin Disease (1)
MedImmune LLC (6) · Abbott (2) · AstraZeneca (2) · AbbVie (1) · AbbVie (prior sponsor, Abbott) (1) · Alaunos Therapeutics (1) · Fred Hutchinson Cancer Center (1) · Hamad Medical Corporation (1) · Merck Sharp & Dohme LLC (1) · mAbxience Research S.L. (1)
United States (8) · United Kingdom (5) · Canada (4) · Chile (4) · Czechia (4) · France (4) · Germany (4) · Hungary (4) · New Zealand (4) · Russia (4) · Spain (4) · Australia (3) · Austria (3) · Bulgaria (3) · Italy (3)
Dr. Khalid Alansari (1) · Genevieve Losonsky, M.D. (1) · Genny Losonsky, MD (1) · Jaymes Holland (1) · Joaquin Valdes (1) · Konstantin M Gudkov, MD (1) · M Pamela Griffin, M.D. (1) · M Pamela Griffin, MD (1) · Michael Boeckh, MD (1) · Oscar Guerra, MD (1) · Pamela Griffin, 301-398-0000 (1) · Pamela Griffin, M.D. (1) · Shigeki Hashimoto, PhD (1) · Sungeen Hill, MD (1)
PMID 19258920, PMID 20008423, PMID 20525274, PMID 22943074, PMID 30760509, PMID 35235733, PMID 38921800, PMID 40602662, PMID 40961423, PMID 42475081
2016 (1), 2019 (1), 2025 (1)